Table 1.
Human islet donor information
| Islet and/or tissue preparation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unique identifier | DON57 | DON43 | DON41 | DON91 | DON5 | DON36 | DON138 | DON120 | DON126 | 08774469 | DON4 | DON54 | DON55 | DON42 | DON61 |
| Donor age, years | 22 | 7 | 8 | 8 | 9 | 11 | 16 | 19 | 19 | 19 | 10 | 20 | 24 | 35 | 55 |
| Donor sex | M | M | F | M | M | M | M | M | M | M | M | M | M | M | M |
| Donor BMI, kg/m2 | 25.7 | 26.6 | 16.1 | 17.2 | 15.5 | 18.3 | 23.2 | 20.1 | 21.2 | 34.1 | 19.3 | 19.4 | 35.5 | 26.8 | 35.6 |
| Donor HbA1c | 11.9 | N/A | N/A | N/A | N/A | 5.8 | 5.9 | 5.1 | 5.0 | 5.8 | N/A | 5.6 | 5.5 | 5.1 | N/A |
| Origin/source of islets | IIAM | NDRI | IIAM | NDRI | NDRI | IIAM | IIAM | NDRI | NDRI | IIDP | NDRI | IIAM | IIAM | IIAM | IIAM |
| Islet isolation center | AHN | AHN | AHN | AHN | AHN | AHN | AHN | AHN | AHN | Univ of Wis | AHN | AHN | AHN | AHN | AHN |
| Donor history of diabetes | Yes | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| Diabetes duration, years | 8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Glucose-lowering therapy at time of death | Insulin (Novolog, Lantus) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Donor cause of death | Anoxia | Respiratory arrest | ICH | Anoxia | Head trauma | Anoxia | Head trauma | Head trauma | Anoxia | Head trauma | Head trauma | Head trauma | Head trauma | Head trauma | CVA |
| Warm ischaemia time, h | DBD | DBD | DBD | DBD | DBD | DBD | DBD | DBD | DBD | N/A | DBD | DBD | DBD | DBD | DBD |
| Cold ischaemia time, h | 12.9 | N/A | N/A | 12 | N/A | N/A | 10.77 | 16.38 | 11.9 | 7.3 | N/A | N/A | 12 | N/A | N/A |
| Estimated purity, % | 75 | 40-50 | 60 | 30 | N/A | 75 | 80 | 90 | 70 | 95 | N/A | N/A | 75 | N/A | N/A |
| Estimated viability, % | 90 | N/A | N/A | 90 | N/A | N/A | 75 | 83 | 70 | 98 | N/A | N/A | 90 | N/A | N/A |
| Culture time prior to shipment, h | N/A | N/A | N/A | 16 | N/A | N/A | 11 | 19 | 18 | 42 | N/A | N/A | 9 | N/A | 36 |
| Glucose-stimulated insulin secretion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Perifusion | Tissue only | Tissue only | Perifusion | Tissue only | Perifusion |
| Handpicked to purity? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Experiment used | In vitro, IHC | In vitro | In vitro | In vitro | In vitro | In vitro | In vitro | In vitro, IHC | In vitro, IHC | In vitro | IHC | IHC | IHC | IHC | IHC |
Samples included in this table have been previously published [1,2].
Abbreviations: AHN, Allegheny Health Network; BMI, body mass index; CVA, cerebrovascular accident (stroke); DBD, donation after brain death (warm ischemia time essentially 0 h); HbA1c, hemoglobin A1c; ICH, intracerebral hemorrhage; IHC, immunohistochemistry; IIAM, International Institute for the Advancement of Medicine; IIDP, Integrated Islet Distribution Program; N/A, not available; NDRI, National Disease Research Interchange; nPOD, Network of Pancreatic Organ Donors with Diabetes.
Reporting checklist from NJ Hart NJ, AC Powers, Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes, Diabetologia, 2019;62:212-222, and V Poitout, LS Satin, SE Kahn, A call for improved reporting of human islet characteristics in research articles, Diabetes, 68(2):239-240.